Latest news with #Innocan
Yahoo
a day ago
- Health
- Yahoo
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added: "We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ Paul J. Christo, Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 * Sources: CDC, U.S. Senate Joint Economic Committee, The Lancet About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - View original content: SOURCE Innocan Pharma Corporation View original content: Sign in to access your portfolio
Cision Canada
a day ago
- Health
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
28-05-2025
- Business
- Cision Canada
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
HERZLIYA, Israel and CALGARY, AB, May 28, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company" or " Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones. Key Business Highlights US $1 million raised through Private Placement - on March 7, 2025, the Company completed a non-brokered private placement of a debenture unit (the " Debenture Unit") to its largest shareholder, Tamar Innovest Ltd., raising US $1 million. First Quarter 2025 Financial Highlights Revenues increased 15% in the first quarter of 2025 to US$7.8 million, compared to US$6.8 million in the first quarter of 2024. This increase in revenue was due to the robust sales performance of Innocan's subsidiary, BI Sky Global Ltd. Gross Profit increased 19% in the first quarter of 2025 to US$7.1 million, compared to US$6.0 million in the first quarter of 2024. Operating loss decreased by 140% to operating profit of US$0.5 million in the first quarter of 2025, compared to operating loss of US$1.2 million in the first quarter of 2024. Corporate Highlights and Business Update Broaden Intellectual Property Coverage for Liposomal CBD Injection Across Asia. The Company reported advancing its efforts to strengthen the protection of its intellectual property across additional Asian markets, following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD. The liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of CBD. Innocan's synthetic CBD-loaded Liposome Injection Platform (LPT-CBD) received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting to advance its development as a non-opioid alternative for chronic pain management. The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain & Company) complements Innocan's global patent applications, strengthening the proprietary value of its novel liposome-based cannabinoid technology. In addition, Innocan reported the filing of this divisional application for its LPT-CBD technology in China which management believes reflects the expertise and commitment of Innocan's team and represents a strategic step in aligning the Company's intellectual property portfolio with its long-term global business objectives. This application aims to protect LPT-CBD. The FDA's Center for Veterinary Medicine (CVM) has granted Innocan a sponsor fee waiver for its LPT-CBD product for the second consecutive year. Following a thorough review, the CVM granted Innocan the 2025 fee waiver, recognizing the Company's continued pursuit of innovative animal drug products and technology. The waiver applies to the Company's LPT-CBD drug product, developed for subcutaneous injection to manage chronic pain in dogs. With growing interest in CBD products among pet owners seeking safe and effective ways to support their pets' health, Innocan's LPT-CBD aims to deliver precise and sustained CBD release from a single injection. This innovation offers a safe and convenient dosing solution for managing chronic pain in dogs, providing benefits for pets of all ages and sizes. Management Comments Iris Bincovich, CEO of Innocan Pharma, commented: "We are very pleased with our strong start to 2025, marked by solid results in the first quarter. This positive momentum reflects the dedication and excellence of our team. We continued to deliver meaningful, customer-centric innovation while maintaining a disciplined approach to operational management. Our progress this quarter reinforces our confidence in our strategic direction and positions us well for continued success throughout the year." "We are moving forward with the FDA approval process for our LPT-CBD delivery system designed for precise dosing and sustained release into the bloodstream, targeting chronic pain relief. Our commitment to innovation and improving patient outcomes remains at the core of everything we do. It's an exciting time for Innocan and our shareholders." Roni Kamhi, CEO of BI Sky Global and COO of Innocan Pharma, commented: "We're very encouraged by the performance of the results in Q1 2025. We are continuing to move forward in both segments "LPT platform - and our consumer wellness. At BI Sky Global, our products continue to gain the trust of millions of customers. We are leveraging our deep expertise in the cosmetics industry along with advanced data analytics to better understand and meet the evolving needs of our customers. Looking ahead, we're focused on further strengthening BI Sky Global's position as a leading company in the beauty and personal care market. The Company's full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its SEDAR+ profile at Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves its primary drug delivery technology, LPT-CBD loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan is a 40% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on advanced targeted online sales. For further information, please contact: NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Yahoo
28-05-2025
- Business
- Yahoo
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
HERZLIYA, Israel and CALGARY, AB, May 28, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones. Key Business Highlights US $1 million raised through Private Placement - on March 7, 2025, the Company completed a non-brokered private placement of a debenture unit (the "Debenture Unit") to its largest shareholder, Tamar Innovest Ltd., raising US $1 million. First Quarter 2025 Financial Highlights Revenues increased 15% in the first quarter of 2025 to US$7.8 million, compared to US$6.8 million in the first quarter of 2024. This increase in revenue was due to the robust sales performance of Innocan's subsidiary, BI Sky Global Ltd. Gross Profit increased 19% in the first quarter of 2025 to US$7.1 million, compared to US$6.0 million in the first quarter of 2024. Operating loss decreased by 140% to operating profit of US$0.5 million in the first quarter of 2025, compared to operating loss of US$1.2 million in the first quarter of 2024. Corporate Highlights and Business Update Broaden Intellectual Property Coverage for Liposomal CBD Injection Across Asia. The Company reported advancing its efforts to strengthen the protection of its intellectual property across additional Asian markets, following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD. The liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of synthetic CBD-loaded Liposome Injection Platform (LPT-CBD) received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting to advance its development as a non-opioid alternative for chronic pain management. The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain & Company) complements Innocan's global patent applications, strengthening the proprietary value of its novel liposome-based cannabinoid addition, Innocan reported the filing of this divisional application for its LPT-CBD technology in China which management believes reflects the expertise and commitment of Innocan's team and represents a strategic step in aligning the Company's intellectual property portfolio with its long-term global business objectives. This application aims to protect LPT-CBD. The FDA's Center for Veterinary Medicine (CVM) has granted Innocan a sponsor fee waiver for its LPT-CBD product for the second consecutive year. Following a thorough review, the CVM granted Innocan the 2025 fee waiver, recognizing the Company's continued pursuit of innovative animal drug products and technology. The waiver applies to the Company's LPT-CBD drug product, developed for subcutaneous injection to manage chronic pain in dogs. With growing interest in CBD products among pet owners seeking safe and effective ways to support their pets' health, Innocan's LPT-CBD aims to deliver precise and sustained CBD release from a single injection. This innovation offers a safe and convenient dosing solution for managing chronic pain in dogs, providing benefits for pets of all ages and sizes. Management Comments Iris Bincovich, CEO of Innocan Pharma, commented: "We are very pleased with our strong start to 2025, marked by solid results in the first quarter. This positive momentum reflects the dedication and excellence of our team. We continued to deliver meaningful, customer-centric innovation while maintaining a disciplined approach to operational management. Our progress this quarter reinforces our confidence in our strategic direction and positions us well for continued success throughout the year." "We are moving forward with the FDA approval process for our LPT-CBD delivery system designed for precise dosing and sustained release into the bloodstream, targeting chronic pain relief. Our commitment to innovation and improving patient outcomes remains at the core of everything we do. It's an exciting time for Innocan and our shareholders." Roni Kamhi, CEO of BI Sky Global and COO of Innocan Pharma, commented: "We're very encouraged by the performance of the results in Q1 2025. We are continuing to move forward in both segments "LPT platform - and our consumer wellness. At BI Sky Global, our products continue to gain the trust of millions of customers. We are leveraging our deep expertise in the cosmetics industry along with advanced data analytics to better understand and meet the evolving needs of our customers. Looking ahead, we're focused on further strengthening BI Sky Global's position as a leading company in the beauty and personal care market. The Company's full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its SEDAR+ profile at About Innocan Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves its primary drug delivery technology, LPT-CBD loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan is a 40% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on advanced targeted online sales. For further information, please contact: For Innocan Pharma Corporation:Iris Bincovich, CEO+1-516-210-4025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: View original content: SOURCE Innocan Pharma Corporation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Market Online
06-05-2025
- Business
- The Market Online
Innocan secures Mexican patent for topical pain-relief technology
Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan's patent application covering its proprietary topical pain-relief formulation The company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief Innocan Pharma stock (CSE:INNO) last traded at $0.16 Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy. The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan's patent application covering its proprietary topical pain-relief formulation. In a media statement, the company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief. Clinical studies have shown that the formulation provides noticeable pain reduction within just 20 minutes of application, underscoring its potential as a next-generation therapeutic solution. The Mexican patent joins previously granted counterparts in the United States and Ukraine, reinforcing Innocan's expanding global IP portfolio. The company also maintains a growing number of pending applications in key jurisdictions worldwide. With this latest development, Innocan Pharma is able to strengthen its presence in Latin America, a region with increasing demand for advanced, non-invasive pain relief solutions. The company continues to explore partnerships and commercialization opportunities to bring its products to market. Innocan Pharma Corp. is active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the company aims to provide non-opioid chronic pain management solutions for both animals and people. Innocan Pharma stock (CSE:INNO) last traded at $0.16. Join the discussion: Find out what everybody's saying about this stock on the Innocan Pharma Bullboard investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
